Innate’s cancer immunotherapy falls short in Phase 2 – BioPharma Dive
|
Innate's cancer immunotherapy falls short in Phase 2
BioPharma Dive Bristol-Myers, which licensed lirilumab from Innate back in 2011, sees lirilumab as potentially complementary to its immunotherapy star Opdivo (nivolumab) and recently read out positive interim results from a Phase 1/2 study combining the two against … |
